Why the study?
Ticagrelor increases bleeding risk due to potent antiplatelet inhibition, prompting awareness of unusual bleeding events such as spontaneous intermuscular hematoma, particularly among individuals of Asian descent.
Highlights the risk of unusual bleeding events such as spontaneous intermuscular hematoma with potent P2Y12 inhibitors like ticagrelor, particularly emphasizing caution in patients of Asian descent.
Answers are grounded in this paper and cite their sources.
May warrant heightened bleeding vigilance with ticagrelor post-PCI; leaves open individualized DAPT duration in high-risk ACS.
Dual antiplatelet therapy is a cornerstone treatment following percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Ticagrelor, a direct-acting potent P2Y12 inhibitor, is superior to clopidogrel in the acute setting of ACS: due to its faster onset and potent antiplatelet inhibition. Thus, ticagrelor is becoming widely recommended as the as the initial treatment following PCI in current guidelines. However, due to its potency, the risk of bleeding is higher. Herein, a report of an unusual case of spontaneous intermuscular hematoma is described. Furthermore, single-nucleotide polymorphisms that may be related to bleeding in ticagrelor using population-based genome-wide association studies were also identified and are discussed. As there is a concern that patients of Asian origin may have a higher risk of bleeding, physicians must be made aware of this risk when prescribing ticagrelor to individuals of Asian decent.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: